Lionheart Ventures is a venture capital firm founded in 2019 that invests in frontier mental-health and 'human flourishing' technologies, including psychedelic medicine and neuromodulation. As of late 2025 it had backed more than 50 companies and maintains dedicated partner focus on the psychedelic sector, with portfolio companies including psychedelic drug developers such as Reconnect Labs.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Clerkenwell HealthSeed - £2.1 million - Oct 10, 2022
- Journey ColabSeries A - $12 million - Sep 7, 2021
Created from documented participation in 2 psychedelic financing rounds. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Oct 10, 2022
Seed - £2.1 million
Clerkenwell Health raises £2.1M to test the new wave of psychedelics treatmentsSep 7, 2021
Series A - $12 million
Fenwick Represents Journey Colab in $12 Million Series A FinancingQuick Facts
- Website
- Visit